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Abstract
Although the introduction of genome-wide association studies (GWAS) have greatly increased the number of genes
associated with common diseases, only a small proportion of the predicted genetic contribution has so far been elucidated.
Studying the cumulative variation of polymorphisms in multiple genes acting in functional pathways may provide a
complementary approach to the more common single SNP association approach in understanding genetic determinants of
common disease. We developed a novel pathway-based method to assess the combined contribution of multiple genetic
variants acting within canonical biological pathways and applied it to data from 14,000 UK individuals with 7 common
diseases. We tested inflammatory pathways for association with Crohn’s disease (CD), rheumatoid arthritis (RA) and type 1
diabetes (T1D) with 4 non-inflammatory diseases as controls. Using a variable selection algorithm, we identified variants
responsible for the pathway association and evaluated their use for disease prediction using a 10 fold cross-validation
framework in order to calculate out-of-sample area under the Receiver Operating Curve (AUC). The generalisability of these
predictive models was tested on an independent birth cohort from Northern Finland. Multiple canonical inflammatory
pathways showed highly significant associations (p 10
23–10
220) with CD, T1D and RA. Variable selection identified on
average a set of 205 SNPs (149 genes) for T1D, 350 SNPs (189 genes) for RA and 493 SNPs (277 genes) for CD. The pattern of
polymorphisms at these SNPS were found to be highly predictive of T1D (91% AUC) and RA (85% AUC), and weakly
predictive of CD (60% AUC). The predictive ability of the T1D model (without any parameter refitting) had good predictive
ability (79% AUC) in the Finnish cohort. Our analysis suggests that genetic contribution to common inflammatory diseases
operates through multiple genes interacting in functional pathways.
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Introduction
The technological development of high throughput genotyping
has provided a powerful tool to examine the genetic basis of
disease through Genome-Wide Association Studies (GWAS).
These studies have considerably increased the number of known
genes associated with common diseases [1]. However, given the
large number of markers typed and the stringent statistical criteria
necessary to minimize false positive hits [2], so far only the most
significant associations have been established. Attempts to increase
the power of GWAS to detect genes with moderate effects by
increasing sample size through meta-analysis may be less effective
in detecting rarer variants, and is limited by inter-population
heterogeneity. It is likely that the genetic associations reported to
date represent only the tip of the iceberg of genes contributing to
disease risk, and that the majority of genes still remain hidden
within the statistical ‘‘noise’’ inherent in this approach [3]. As a
result, much of the genetic information which may emerge from
GWAS remains unutilised and the question of how many genes
contribute to disease susceptibility, how they interact to cause
disease, and the extent to which disease pathogenesis might be
genetically predicted remains largely unknown [4].
Disease susceptibility is likely to depend on the cumulative effect
of variants in multiple genes interacting in functional pathways.
We use the term ‘‘interacting’’ in the biological sense to define
genes whose products act within functional pathways, to alter the
function or expression of other components of a pathway leading
to a biological output. This ‘‘pathway’’ interaction is distinct from
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e8068the statistical use of the term to define epistatic interaction, which
is defined in the context of a particular phenotype and can be
tested by looking at the correlation structure of mutations
conditional on a phenotypic outcome (case vs. control for
example).
If we consider the genetic regulation of the immune response,
multiple genes contribute to the response to any pathogen - some
acting as positive and others as negative regulators [5] (Figure 1).
The pattern of gene variants within inflammatory pathways will
determine the intensity and nature of an individual’s immune
response to pathogens and thus the outcome of different infectious
diseases encountered throughout life [6,7].
The same gene variants which result in rapid activation of a
vigorous inflammatory response to infection may have the
disadvantage of increasing the risk of auto-immune and inflam-
matory diseases later in life [8,9]. Pro-inflammatory mediators
such as TNF, IL-12, IL-1, IL-6 and IFN-c, essential for
containment of microbial pathogens [10,11], are also associated
with inflammatory processes seen in common auto-immune
diseases such as RA [12], CD [13], or T1D [14]. Conversely,
treatments that reduce inflammation, such as anti-TNF therapy
for CD or RA [15] are associated with increased risk of
opportunistic infection [16], suggesting that pathways involved
in inflammatory diseases are also involved in resistance to
infectious diseases. We postulated that the genetic contribution
to common inflammatory diseases would be determined by
multiple gene variants in the same inflammatory pathways
involved in host response to infectious diseases (Figure 1).
We show here that the application of a pathway approach to
GWAS yields new insight into the biology of CD, T1D and RA
pathogenesis by implicating novel biological pathways as well as
identifying new gene associations in known pathways. We also
show that multiple SNP variants in these pathways can be used to
build predictive models of disease risk, thus providing a new
picture of how multiple gene variants combine to contribute to
disease risk.
Results
Shared and unique disease pathways for each disease
We used the novel statistical approach (described in detail in the
methods section) to evaluate the combined effect of multiple
genetic variants in the genes comprising canonical immune and
inflammatory pathways.
Highly significant associations were observed between key
inflammatory pathways and the three inflammatory diseases
(Table 1). Jak-STAT signalling, antigen processing and presenta-
tion, T cell activation pathway, cell adhesion molecules,
hematopoietic cell lineage and NK cell mediated cytotoxicity
showed high levels of significance in all three autoimmune diseases
(P,10
24 to P,10
220). However certain pathways showed
evidence for association with one disease; the pathways of
NOD2 (P,10
24 to P,10
215), IL-23 and TNF (P,10
220), IL-
12 and TGF-b (P,10
26), TLR2 signalling (P,10
25 to 10
29),
classical MAPK (P,10
210) and B cell activation (P,10
28) with
CD; TLR3 (P,10
24), T-cell activation via PLC and via NFAT
Figure 1. Inflammatory response to a pathogen. Pathogen recognised by pattern recognition receptors on phagocytic cell (A) or plasma
opsonins (I). Signal induction (B) and first order inflammatory genes (C) are induced leading to release of inflammatory signals. These bind to
receptors (D), leading to activation of signal transduction pathways and gene induction of second order inflammatory mediators (E, F). These act as
effectors of the inflammatory response (Red Arrow) or as positive or negative regulators. Inflammation upregulates cell adhesion molecules (J) and
those involved in transendothelial migration (K). Genetic variants (A–J) will interact to alter the intensity and nature of the response, and may
determine different outcomes. Individuals making an excessive inflammatory response may succumb to overwhelming inflammation, while those
making an inadequate response may fail to clear the pathogen. EC=endothelial cell.
doi:10.1371/journal.pone.0008068.g001
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PATHWAY CD T1D RA HT BD CAD T2D
Pattern recognition receptors
TLR2
1 3.5E-05 0.029 0.041 0.257 0.187 0.386 0.357
TLR2/1
1 9.1E-06 0.030 0.026 0.197 0.185 0.318 0.367
TLR2/6
1 2.4E-05 0.020 0.065 0.129 0.129 0.179 0.316
TLR3
1 0.001 3.3E-04 0.037 0.319 0.198 0.246 0.145
TLR4 (MyD88 dependent)
1 0.020 0.010 0.040 0.199 0.102 0.469 0.335
TLR4 (MyD88 independent)
1 0.018 0.018 0.029 0.152 0.124 0.343 0.262
TLR5/TLR7/TLR8/TLR9
12 0.127 0.062 0.397 0.380 0.154 0.342 0.119
TLR2-IRF5 2.7E-06 0.225 0.001 0.116 0.085 0.389 0.477
TLR2/1-IRF5 3.1E-09 0.228 0.001 0.129 0.066 0.453 0.442
TLR2/6-IRF5 8.1E-05 0.171 0.001 0.179 0.066 0.102 0.330
TLR4 (MyD88 dependent)-IRF5 0.022 0.076 0.017 0.173 0.078 0.555 0.482
TLR5/TLR7/TLR8-IRF5
2 0.441 0.804 0.032 0.315 0.013 0.394 0.004
TLR9-IRF5 0.002 0.058 1.6E-06 0.220 0.112 0.638 0.361
Signal transduction
Jak-STAT signalling 2.5E-07 1.9E-12 4.4E-09 0.005 0.011 0.166 0.045
MAPK: All 7.7E-09 1.5E-06 0.119 0.005 0.054 0.020 0.003
MAPK: Classical 1.8E-10 0.001 0.164 0.009 0.121 0.033 0.001
MAPK: JNK & p38 2.2E-06 0.027 0.139 0.053 0.158 0.046 0.030
NFKB 0.030 0.016 0.010 0.842 0.533 0.333 0.294
NOD1
1 0.097 0.324 0.633 0.003 0.141 0.001 0.489
NOD2 (via GRIM19)
1 4.4E-04 0.055 0.237 0.184 0.102 0.205 0.210
NOD2 (via RICK)
1 1.3E-15 0.587 0.528 0.005 0.151 0.045 0.287
Second order cytokines
IL-1
1 0.003 0.217 0.127 0.101 0.157 0.516 0.496
IL-6 3.5E-04 4.2E-04 0.064 0.140 0.826 0.221 0.426
IL-10 8.4E-06 2.1E-04 0.083 0.378 0.683 0.116 0.836
IL-12 4.9E-06 4.32E-03 0.003 0.324 0.949 0.523 0.747
IL-18 0.017 0.062 0.032 0.220 0.391 0.287 0.287
IL-23 0.0E+00 0.017 0.063 0.012 0.709 0.637 0.301
TNF
1 0.0E+00 0.017 0.026 0.045 0.244 0.635 0.283
TGF-b 2.6E-05 0.004 0.035 0.102 0.502 0.155 0.218
Antigen processing and presentation
All
1 1.4E-04 0.0E+00 0.0E+00 0.012 0.016 0.256 0.577
MHC I 0.073 0.0E+00 0.0E+00 0.291 0.266 0.420 0.521
MHC II 1.9E-05 0.0E+00 0.0E+00 0.021 0.043 0.810 0.545
B–cell activation
All
1 5.2E-08 0.005 0.656 0.005 0.026 0.196 0.006
AKT
1 0.039 0.550 0.223 0.015 0.021 0.059 0.004
AP1 7.6E-11 0.037 0.578 0.146 0.136 0.403 0.004
NFAT 1.7E-04 0.002 0.702 0.010 0.009 0.221 0.067
PKC
1 0.037 0.050 0.553 0.245 1.1E-04 0.323 0.135
T–cell activation
All
1 2.5E-11 1.3E-07 2.4E-05 4.1E-05 0.004 0.069 0.002
AP1 5.3E-07 0.002 0.112 0.124 0.293 0.516 0.003
NFAT 0.004 1.0E-04 0.025 0.021 0.004 0.452 0.047
PLC
1 0.002 1.3E-04 0.009 0.028 0.153 0.480 0.007
ICOS/CD28
1 4.1E-05 0.227 0.029 0.001 0.060 0.024 0.352
Cytokines/receptors 4.3E-04 6.0E-06 2.5E-06 0.156 0.005 0.055 0.123
Cytokines/receptors/Jak-STAT/suppressors 2.4E-04 1.2E-09 1.1E-04 0.007 0.011 0.023 0.014
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24) and ABC transporters (P,10
216) with T1D; TLR9
signalling via IRF5 (P,10
26) and purine metabolism (P,10
25)
with RA (Table 1).
Almost all of the pathways under investigation showed no
evidence of association with the non-inflammatory diseases
(Table 1). However, some signal of association was detected
in pathways with previously identified or biologically plausible
link to a non-inflammatory disease. For instance, association
between the B cell signalling via protein kinase C (PKC)
pathway and bipolar disorder is consistent with reports that
PKC activity has a role in pathophysiology of bipolar disease
[17].
No association was seen for metabolic pathways that are not
expected to have a biological link to the inflammatory diseases
(Table 1 and web-based additional material Table 20).
Common and unique key gene variants for each disease
To identify the genes and SNPs predominantly responsible for
the pathway effect, we applied variable selection and model fitting
on all the SNPs within associated pathways, within the framework
of 10-fold CV. The models developed during CV consisted on
average of 205 SNPs (149 genes) in T1D, 350 SNPs (189 genes) in
RA and 493 SNPs (277 genes) in CD (Table S1). For all, except
the smallest pathways, the signal for pathway association arises
from the cumulative effect of many gene variants (Figure S1).
Furthermore the significance of the majority of pathways was not
dependent on the established significant (single SNP trend test
P,5610
27) hits, as when the pathway statistic was repeated after
excluding significant hits, and known associations, the pathway
statistic remained significant for the majority of associated
pathways (Table S2).
We reasoned that the genes selected in all ten CV models
represent a ‘‘core’’ set of genes showing consistent association with
the disease. This set comprised a total of 52 genes for T1D, 88
genes in RA and 118 genes in CD as shown in Figure 2 (SNPs
shown in web-based additional material Tables 11–13). Only 12
genes were common to all three diseases, 11 were shared by CD
and T1D, 5 shared by T1D and RA, and 26 were shared by RA
and CD. The majority of identified genes were unique to each
disease. Common genes included the major histocompatibility
complex HLA-DQB1, HLA-G and HLA-C from the antigen
processing and presentation pathway; PPP3R2, PLA2G4A,
ITPR1, VAV3 and PAK7 from the T cell activation pathways;
and the cell adhesion molecules ALCAM, NLGN1, ITGA1 and
the cadherin CDH2.
Several of the genes we identified have been associated with
autoimmune diseases in previous GWAS [18–22]. Of note is that
our analysis identified IL12B, ICOSLG, STAT3, CCR6 for CD
PATHWAY CD T1D RA HT BD CAD T2D
IFN-c 1.7E-05 8.6E-06 0.018 0.065 0.089 0.186 0.630
Signalling molecules and interaction
Cell adhesion molecules: All 0.0E+00 0.0E+00 0.0E+00 0.081 3.1E-04 4.6E-04 2.0E-04
APC: T cell 5.0E-06 0.0E+00 0.0E+00 0.211 0.001 0.618 0.184
Tc cell: target cell 0.010 0.0E+00 0.0E+00 0.577 0.284 0.561 0.438
Th cell: B cell 2.5E-04 0.0E+00 0.0E+00 0.068 0.035 0.363 0.554
Leukocyte: platelet 0.208 0.868 0.631 0.208 3.5E-05 0.680 0.139
Leukocyte: endothelial cell 0.029 0.095 0.257 0.194 2.2E-04 0.190 0.452
Neural cells 7.6E-05 0.123 0.125 0.191 0.045 0.001 0.001
Cytokine-cytokine receptor interactions 4.2E-15 2.7E-12 0.002 0.042 0.026 0.194 0.104
Others
ABC transporters 0.021 2.2E-16 0.004 0.350 0.003 0.276 0.166
Cell communication 0.014 8.3E-05 0.007 0.064 1.6E-04 0.051 0.009
Complement: All 0.080 0.323 0.051 0.245 0.551 0.484 0.206
Haematopoietic cell lineage: All 6.3E-10 0.0E+00 0.0E+00 0.006 2.8E-04 0.019 0.070
Leucocyte transendothelial migration 0.013 0.575 0.102 0.418 0.003 0.059 0.203
Natural killer cell mediated cytotoxicity 3.3E-10 0.0E+00 1.4E-09 0.003 0.001 0.100 0.431
Neutrophil activation 4.5E-05 0.002 0.043 0.061 0.290 0.043 0.605
Purine metabolism 1.04E-02 0.026 3.2E-05 0.174 0.474 0.010 0.367
Pyrimidine metabolism 7.02E-02 0.160 0.039 0.389 0.377 0.590 0.280
Type 1 diabetes pathway from KEGG 4.8E-07 0.0E+00 0.0E+00 0.231 0.045 0.672 0.940
Non-inflammatory pathways
Urea cycle 0.928 0.081 0.771 0.318 0.153 0.257 0.069
Citrate Cycle (TCA cycle) 0.829 0.935 0.331 0.197 0.235 0.761 0.327
Arachidonic Acid metabolism 0.411 0.844 0.289 0.157 0.806 0.338 0.192
1Addition of NFKB did not change the result.
2Although shown together, these were considered as separate pathways.
3Additional pathways analyzed are shown in Table S3 & S4.
doi:10.1371/journal.pone.0008068.t001
Table 1. Cont.
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three separate GW scans [22], as well as IL18RAP which was
identified in a recent case-control study [23]. For T1D, STAT4
was associated with the disease in follow-up candidate gene studies
[24,25] as was PRKCQ [26–28] (Figure 2). The previously
identified genes found by our approach include for T1D, genes in
the HLA region, CTLA4, PTPN22 and IL-2RA. For RA;
PRKCQ and GZMB (these showed nominal significance
P,10
24 to 10
25 in the WTCCC study), IL2RA, IL2RB and
TNFAIP3 (these showed a modest evidence of association P,10
25
to 5610
27 in WTCCC study), and MICA [29–31] as well as IRF5
[32,33] that was confirmed by meta-analysis [34]. Similarly for
CD, the well established associations with NOD2, IL23R and the
recently implicated IL12B and STAT3 were all confirmed.
However, in addition to these established associations we also
identified other components of key pathways contributing to
disease, such as RIPK2 and MAP3K7 from the NOD2 pathway in
CD. We also identified genes in novel pathways: in T1D, a
number of genes controlling T cell activation were selected
including the calcium channel ITPR1, the calcium dependent
phospholipase PLA2G4A, the regulatory subunit of calcineurin
PPP3R2 and the calcineurin dependent transcription factor
NFATC2 suggesting a role for calcineurin/nuclear factor of
activated T-cells (NFAT) signalling in susceptibility of type 1
diabetes.
TNF plays a critical role in inflammation in RA and CD [12,13]
and has been a major target for therapeutic antibody treatments.
The TNF pathway was significant in CD only, and key
components selected include two enzymes that are regulators of
NF-kB signalling–a negative regulator of NF-kB, the deubiquiti-
nating enzyme CYLD [35] (rs7342715) and TNFAIP3
(rs7753394) both a deubiquitinating enzyme and a ubiquitin ligase
[36]. Both of these enzymes deubiquitinate NEMO and, when
knocked out in vivo, lead to inflammatory bowel disease [37].
Genetic variants near TNFAIP3 have recently been associated
with RA (see below) as well as ulcerative colitis and CD [18,38]
and was associated in our study for both CD (rs7753394) and RA
(rs6920220) (see below).
Figure 2. Genes identified by variable selection in all 10 folds of cross-validation for T1D, RA, CD. Key genes that showed consistent
association with each disease had at least one mapping SNP selected in all 10 logistic models of CV. Genes are grouped in their pathways, which are
shown as bubbles. Pathways are colour-coded in agreement with Table 1 and Supplementary Tables. Overlapping bubbles represent pathways that
share key genes. Underlined genes correspond to associations that have been reported in previous association studies.
doi:10.1371/journal.pone.0008068.g002
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we found that only TLR9 signalling via IRF5 was significant
among TLR pathways. TLR9 is constitutively expressed on B cells
that are critical in the pathogenesis of rheumatoid arthritis [39].
The plausibility of this pathway is strengthened by the finding that
several genes downstream of TLR9 were also selected; IRF5
(rs3807306) and the negative regulators SOCS1 (rs11074956,
rs243325) and TNFAIP3 (rs6920220). It is of interest that recent
studies show an association of the IRF5 gene with RA [32,33], and
2 studies link region 6q23, flanked by TNFAIP3 and OLIG3 with
RA susceptibility [40,41].
Genomic prediction of disease risk
We next investigated how well the combination of gene variants
selected by variable selection can predict disease in individuals. We
used ten fold cross-validation (see methods) to build predictive
models on 90% of the cases and controls, which are then tested on
the remaining 10%. The process was then repeated using a
different 90% and 10% of the cohorts on each occasion. The
sensitivity and specificity of the models for each disease are shown
in ROC curves (Figure 3A–C). The area under the average ROC
(AUC) is 91%, 85% and 60% for T1D, RA and CD respectively,
which correlates inversely to the number of SNPs in the models for
each disease.
The predictive models, as expected, contained some of the well-
established markers associated with each disease. To evaluate the
extent to which prediction was driven by these significant hits, we
split each model into two models without any refitting of the
coefficients; a model excluding all SNPs with single-SNP
P,5610
27 as well as any SNPs in LD with these (r2§0:3);
specifically for T1D and RA we also removed any SNPs that
mapped to the MHC gene clusters in chromosome 6 [42] and a
model with only these excluded SNPs. As shown in Figure 3, a
large proportion of the predictive power comes from established
associations (Figure 3A–C red curves, T1D AUC^0:84,R A
AUC^0:7,C DAUC^0:58), however the SNPs identified by the
pathway analysis have predictive power in the absence of these hits
(Figure 3A–C blue curves, T1D AUC^0:7,R AAUC^0:81,C D
AUC^0:56) and also increase the predictive power when added
to the significant hits (Figure 3A–C green curves, T1D
AUC^0:91,R AAUC^0:85, CD AUC 0.60). In all three
diseases, the pathway-derived models had greater predictive value
than the significant hits alone. Remarkably for RA, the SNPs
identified by the pathway approach, excluding the significant hits,
have higher predictive value than the significant hits on their own.
Validation Study
In order to test the generalisability of our approach to other
populations, and to investigate its applicability in the general
population (rather than a case-control design), we tested the T1D
predictive models in the Northern Finnish Birth cohort (NFBC).
Each of the 10 T1D models trained on different 90% subsets of the
WTCCC samples were used to calculate disease risk, without any
parameter refitting. As the NFBC was typed on a different
platform to the WTCCC, those SNPs which were not in common
between the two genotyping platforms were imputed (see
methods). The 10 T1D models trained on 90% of the WTCCC
predicted on average over 60% of the Finnish T1D cases with a
false positive rate of 10%, compared to 73% in the original UK
sample (Figure 3D, green curve AUC^0:79). The single model
trained on the entire WTCCC T1D case-control dataset achieved
almost the same predictive power (Figure S2, green curve,
AUC^0:77). Although the significant SNPs (P,5610
27) ac-
counted for a considerable proportion of the predictive power
(Figure 3D and Figure S2, red curves, AUC^0:76), the additional
SNPs identified by our approach contribute to the predictive
power (Figure 3D and Figure S2, green curves) and have
predictive value on their own (Figure 3D and Figure S2, blue
curves, AUC^0:71).
Visualisation of genomic risk
We reasoned that each SNP has a different effect on disease
predisposition either increasing or decreasing the risk due to its
functional effect on the regulation of the overall pathway output
(Figure 1). We categorized SNPs as adverse or protective on the basis
of their coefficient in the CV model (relative to the minor allele for
additive effects). As shown in Figure S3, each SNP exerts an adverse
or protective effect through dominant, recessive, additive or
heterozygous modes. In T1D for example, there are two adverse
HLA-DQB1 variants (rs9273363/rs9275418) and two protective
HLA-DQA1 variants (rs9272723/rs9270986), and PTPN22
(rs6679677) is adverse for both T1D and RA. Figure S3 also
illustrates the differing magnitude of effect of individual SNPs, with
many showing only a small effect, but less common variants having
more powerful adverse or protective effects.
In order to display for any individual, the pattern of rare and
common variants, and the protective or adverse effect of each variant,
in Figure 4 we plot for every individual (columns) their genotype at
each SNP. We used red to indicate an adverse and green a protective
SNP (rows). The intensity of colour reflects the effect of the SNP in
the model (Methods S1). This provides a way of visualising the
predictive models. Each individual seems to carry a unique
combination of adverse and protective variants, which may represent
a personal ‘‘genomic fingerprint’’ of disease predisposition. Despite
the vast number of different combinations, a pattern is revealed
where patients (left side) compared to healthy individuals (right
side) are seen to carry a higher number of adverse genotypes and
fewer number of protective genotypes and vice versa.
Discussion
Our pathway analysis has shown that variation in conserved
canonical inflammatory pathways underlies genetic susceptibility
to T1D, CD, and RA. Although a number of pathways we have
identified contain genes implicated in susceptibility to these
diseases in previous single SNP based studies, our analysis presents
a new perspective on the number of contributing pathways, the
number of genes within pathways that interact to determine
disease occurrence, and also identifies novel pathways and genes
associated with each disease. Furthermore our analysis provides
new insight into the pathways that are common as well as those
unique to the three diseases, and suggests that genetic influence
operates through functionally interacting genes.
Pathway-based approaches have been employed in previous
studies [43–48], but have focused less on the underlying
mechanisms that affect disease occurrence. Our approach not
only enables the pathways associated with disease to be identified,
but provides a method to identify the individual genes and their
SNPs within the pathway that are predominantly responsible for
the genetic effect. Our approach relies on the existence of well-
defined biological pathways involved in inflammation, and our
hypothesis that the cumulative effect of mutations in these
pathways are likely to affect disease susceptibility in T1D, CD
and RA. In many other diseases the relevant pathways are not yet
as clearly identified. However, as the understanding of the function
of genes increases [49,50], the same approach may be readily
applied to other diseases.
Pathway Analysis of GWAS
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and RA has been increasing progressively through the use of meta-
analysis. In order to place the findings of our pathway-based
approach in the context of what has been found using
conventional single SNP analysis in the original WTCCC study,
in previous studies or in more recent meta-analysis, we have
tabulated in web-based additional material Tables 17–19, the
previously reported associations for CD, RA, and T1D and related
these to the genes implicated in our analysis. These tables show
that several genes, which were not significant in the initial
WTCCC analysis, but were identified by our approach, have now
been confirmed in subsequent meta-analysis or candidate gene
studies. One obvious concern of the pathway approach is that it
can only evaluate the genetic contribution of genes known to act
within pathways. As shown in web-based additional material
Tables 17–19 several of the previously reported associations are
genes not present in our inflammatory pathways, and thus are
‘‘missed’’ by our approach. However, there are many other genes
Figure 3. ROC curves showing the average predictive performance for T1D, RA and CD. True positive rate and false positive rate for
predicting case/control status for A) type 1 diabetes, B) rheumatoid arthritis, C) Crohn’s disease on the WTCCC dataset and D) ROC showing the
average predictive performance of the T1D models built on the UK WTCCC dataset and applied to the 4,763 subjects in the Northern Finland 1966
Birth Cohort. Each colored line is the average ROC of the 10 models fitted during CV. The green curves show the performance of the models, as built
by the variable selection algorithm. Blue curves show the performance of the same models with all significant hits (individual trend test P,5610
27)
and SNPs in LD (r2§0:3) removed. Red curves show the predictive performance of the models formed only by the previously excluded SNPs
(significant hits and SNPs in LD). In T1D (A) the area under the average ROC curves is 91%, 71% and 84%, in RA (B) it is 85%, 81%, 70% and in CD (C)
60%, 56%, 58% for the pathway-derived models (green-curves), the pathway-derived models excluding the significant hits (blue curves) and the
significant-hit models (red-curves) respectively. In (D) the AUC of the green, blue and red ROC is 0.79, 0.71 and 0.76 respectively.
doi:10.1371/journal.pone.0008068.g003
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by meta-analysis or in large studies subsequent to WTCCC studies
and which were ‘‘missed’’ by the WTCCC single SNP analysis.
These genes suggest that the pathway approach may be a useful
method for identification of real associations without recourse to
meta-analysis, and using smaller cohorts than required for some of
the confirmed associations. In web-based additional material
Tables 17–19 we also show that there are genes that are implicated
by our pathway-based approach which have not been found in
previous studies, and thus require validation in independent data
sets. While these associations have yet to be replicated, their
predictive performance during cross-validation and the validation
of the gene set identified on the WTCCC in predicting T1D in the
NFBC suggests that these genes are plausible associations. As data
from other studies on CD and RA become available, these novel
associations can be validated either in GWAS or in candidate gene
studies.
We have identified gene/SNP sets within inflammatory
pathways which appear to have predictive value for disease
occurrence. We stress that our evaluation of these gene sets as
predictive markers of disease status was not aimed at assessing
their clinical use in disease prediction. Instead we aimed to use the
predictive performance of the models as an indication of the
importance of genetic influence on disease occurrence [46,51].
The validation of our T1D models on a different population
provides the most stringent test of our approach. The predictive
models trained on the UK WTCCC cohort predicted develop-
ment of T1D in over 60% of the Finnish patients who developed
disease by age 30 (with a false positive rate of 10%). Although the
level of prediction was lower than that on the WTCCC cohort
(true positive rate=73%, false positive rate=10%), which may
suggest that the initial predictive power on the WTCCC was over-
inflated, the lower performance may also be due to biological or
technical factors, such as the use of imputed SNPs in the Finnish
samples, and because the Finnish population differs from UK
Caucasians in haplotypic structure [52]. However, the predictive
power was still higher than achieved in other studies [53–55].
Definitive assessment of the predictive performance of models
developed on one cohort (such as the WTCCC) will require
validation studies to be undertaken on a second cohort from the
same population and ethnic groups, and with direct genotyping
undertaken on the same SNPs.
Although much of the predictive power in T1D was due to the
MHC complex effects and other known associations, the
remaining SNPs in our models have substantial predictive value
in their own right, and remarkably in RA, the genes not meeting
GWAS significance provide better predictive value than the
significant hits alone. The lower predictive performance of the
models in CD may reflect that this disease (which has a number of
well recognised clinical phenotypic subgroups [51]) is more
heterogeneous in its genetic origins, a possibility also suggested
by the higher number of SNPs identified by variable selection in
CD.
The strategy of using curated biological pathways has some
limitations. As noted previously [56], this approach is dependent
on the quality and completeness of the curated biological pathways
used as input. Another obvious concern is that it can only evaluate
the genetic contribution of genes known to act within pathways.
Genes which are not yet within the accepted ‘‘canonical’’
pathways used for the analysis will be missed by our approach.
For example some of the genes which were associated with T1D in
the recent meta-analysis [26], were not included in the current
curated pathways (e.g. PTPN2, C1QTNF) included as a starting
point for our analysis. However, biological understanding of the
Figure 4. Variant SNPs carried by cases with type 1 diabetes and controls. (a) Predicted probability of being a case, (b) Actual case or
control status. Patients shown in red and controls in green. The model correctly assigns the majority of cases at the extreme left, and controls at
extreme right, with less predictive ability in the middle. (c) Individual patients or controls are displayed in columns and each row represents one SNP.
Red indicates an adverse and green a protective SNP. Intensity of colour indicates disease log-odds from the predictive model. The magnified sections
show regions where very marked differences between cases and controls can be readily seen.
doi:10.1371/journal.pone.0008068.g004
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available lists of ‘‘canonical’’ pathways will inevitably expand
rapidly in the future as new data on function of genes becomes
available. The strength of the single SNP approaches which have
been used in most previous GWAS analysis is that they are
‘‘hypothesis free’’ and can bring to light associations with genes not
previously suspected as having roles in a particular disease. Our
pathway approach may be useful to complement the findings of
significant associations at the single SNP level. Once a gene has
been implicated by association at the single SNP level, all the other
genes in the pathway in which the associated gene functions can
then be included in the analysis, to identify other genes which may
be acting in concert to produce the overall genetic effect.
Defining whether a particular SNP is part of, or regulates a gene
can also be problematic, and can result in functionally important
trans-regulatory SNPs being missed and will also miss the effect of
SNPs in gene deserts. Large pathways or pathways with genes that
reside in large LD blocks are likely to inflate the pathway statistic,
although we accounted partially for this potential bias via the
permutations procedure. These limitations however can each be
addressed as functional pathways become better defined and
understanding of gene function improves, through linking genomic
and gene expression and/or proteomic data.
Our approach suggests a new picture of how variation in
multiple genes linked in functional pathways contributes to
inflammatory disease susceptibility and provides a useful tool to
reveal the hidden information of GWAS that would be missed in
single SNP analysis. We suggest that a biological pathway-based
approach is likely to be valuable in elucidating the genomic
mechanisms underlying common diseases and may identify new
pathways as therapeutic targets.
Methods
The flow chart in Figure S4 outlines the sequential steps in our
analysis, and more detailed statistical methods are described in the
supplementary section (Methods S1 and S2 and Figure S5).
Patient Cohorts
The study was approved by the Clinical Research Governance
Office of Imperial College London (Reference ICREC_9_1_11).
All data were analyzed anonymously. We analysed the raw
anonymous genotypic data from the Wellcome Trust Case
Control Consortium (WTCCC) study on 14,000 Caucasian UK
patients and 3000 controls genotyped on the Affymetrix 500K
mapping array. The cohort included 7 common diseases; Crohn’s
disease, rheumatoid arthritis, type 1 diabetes, hypertension, type 2
diabetes, bipolar disorder and coronary artery disease and has
been described in detail [18]. For the validation study we used
anonymous data from 4,763 individuals in the Northern Finland
1966 Birth Cohort (NFBC 1966) [57] genotyped on the Illumina
Infinium 370cnvDuo array, thirty of whom were ultimately
diagnosed as having T1D.
Pathway selection
We selected key canonical pathways associated with the innate
and acquired immune response to pathogens (Figure 1 and Table
S3 and S4), defined using the KEGG [58] and Ingenuity Pathways
Analysis 6 databases, supplemented from the literature. We
examined 84 pathways containing 1415 genes and 20,309 SNPs
within 10KB of the genes. As negative controls, we selected
metabolic pathways which biologically were not expected to
contribute to inflammatory disease susceptibility (Table S3 and
web-based additional material Table 9). Genes in all examined
pathways are shown in the web-based additional material located
at http://www1.imperial.ac.uk/medicine/people/l.coin/. A sum-
mary of the numbers of genes and SNPs used for each stage of
analysis is shown in Table S1.
Test for pathway association: cumulative trend test
statistic
To evaluate the overall genetic contribution of a given pathway,
we developed a cumulative trend test statistic CTpathway by
summing the Armitage trend test statistic over all of the SNPs in
the pathway. We estimated the parameters of a parametric
approximation of the null distribution of the statistic by fitting a
skew normal distribution to results obtained from 1000 random
permutations of case/control labels. This procedure was carried
out separately for each disease and given pathway. Pathway
significance was defined at a~0:0005, i.e. significance level
a~0:05 Bonferroni corrected for ,100 pathways.
Variable selection and logistic regression
To identify the genes (and SNPs) predominantly responsible for
the pathway effect, we collected the SNPs within pathways with
CTpathway P,0,005 and applied HyperLasso [59] a variable
selection algorithm designed to build a predictive model of disease
risk. HyperLasso [59] fits a logistic regression model while
performing variable selection to generate models with relatively
few predictors. Variable selection and model fitting were
performed under the framework of 10-fold cross validation (CV).
Model evaluation and ROCs
To evaluate the performance of the predictive logistic models,
we displayed the average sensitivity/specificity across all 10 trials
via Receiver Operating Characteristic (ROC) plots and calculated
the area under the ROC curves (AUC) [60].
Validation in an independent cohort
The validation of our predictive models on an independent
dataset was carried out in two ways; to achieve direct
comparability between the level of prediction on the WTCCC
data and the NFBC 1966 data, we used the same 10 models
trained during cross-validation on a 90% subset of the WTCCC
dataset on the independent dataset; we also fitted a single model
on the entire WTCCC data and tested its ability to predict T1D in
the subjects of the NFBC.
Supporting Information
Figure S1 Fraction of the associated pathways selected on
average by variable selection. The bar charts show for each disease
the average number of genes in a pathway, selected during
variable selection, divided by the total number of genes in that
pathway and expressed as a percentage. Only associated pathways
are shown. The total number of genes in a pathway are shown in
parenthesis after the pathway name. The colour-coded bars for
each disease are not stacked (i.e. they are not summated).
Found at: doi:10.1371/journal.pone.0008068.s001 (0.85 MB TIF)
Figure S2 Single model fitted on the entire WTCCC T1D cases
and controls when applied to the Northern Finland 1966 Birth
Cohort. The area under the ROC curve for the pathway-derived
model is 0.77 (green curve), for the same model but with all
significant hits (single SNP trend test P,5610
27) and the SNPs in
LD (r
2$0.3) excluded is 0.69 (blue curve) and for the model with
only the excluded SNPs is 0.74 (red curve).
Found at: doi:10.1371/journal.pone.0008068.s002 (0.43 MB TIF)
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models of disease risk. Minor allele frequency vs. beta coefficient
for each SNP retained in the fitted logistic regression model from
first round of cross-validation. Additive, recessive, dominant and
heterozygous effects are displayed by black squares, blue dots,
mauve triangles and cyan diamonds respectively. Adverse vs.
protective SNPs have a positive vs. negative beta value
respectively. Labels are given for all SNPs with beta greater than
0.25. In T1D there are a number of SNPs with large adverse
effects acting in a dominant and additive manner and hence a
significantly different sum of additive (t-test, P=2610e-06) and
dominant (P=2610e-06) effects between cases and controls. In
RA, we observe SNPs with large additive adverse and protective
effects resulting in a significant difference in the sum of additive
(P=2610e-14), as well as dominant (P=6610e-04) and recessive
(P=0.014) effects. In CD there are fewer SNPs with large effect
yet still significant differences for additive (P=4e-03) and
heterozygous (P=0.04) cumulative effects.
Found at: doi:10.1371/journal.pone.0008068.s003 (1.17 MB TIF)
Figure S4 Stepwise procedure for the pathway-based analysis.
Found at: doi:10.1371/journal.pone.0008068.s004 (0.66 MB TIF)
Figure S5 Histogram, density function and q-q plots of various
distribution fits to permutation data of the cumulative trend test
statistic. The plot on the top left corner shows the histogram and
the fitted skew normal density function of the cumulative trend test
statistic calculated from 10,000 permutations of cases/control label
for the IL-1 pathway in CD and the top middle plot shows the
QQ-plot of the fitted skew normal distribution. The next four plots
correspond to QQ-plots of four distribution fits to the same null
distribution. The P-value of Kolmogorov-Smirnof goodness of fit
test statistic is depicted in the legend of each plot.
Found at: doi:10.1371/journal.pone.0008068.s005 (0.41 MB TIF)
Table S1 Summary statistics at each stage of the analysis.
Found at: doi:10.1371/journal.pone.0008068.s006 (0.02 MB
XLS)
Table S2 P-values of the pathway statistic over the examined
pathways without any SNPs with single-marker P,5610
27.P -
values in bold and scientific format correspond to pathways that
preserved their statistical significance even after the removal of the
significant hits. P-values in italics stand for pathways that were
statistically significant with the significant hits included but not
without.
Found at: doi:10.1371/journal.pone.0008068.s007 (0.02 MB
XLS)
Table S3 List of examined pathways with the corresponding
numbers of genes and SNPs. The column of significant hits shows
the number of SNPs with individual trend test P,5610
27 within
each pathway. Bold highlighting denotes association of a pathway
with the disease. The last column shows the table index in the web-
based additional material which contains lists of genes for every
pathway.
Found at: doi:10.1371/journal.pone.0008068.s008 (0.02 MB
XLS)
Table S4 Additional inflammatory pathways analyzed. These
pathways are not shown in Table 1, either because they showed no
association to any disease (e.g. pyrin) or showed association but
were combined into one to be used for downstream analysis (e.g.
haematopoietic cell lineage).
Found at: doi:10.1371/journal.pone.0008068.s009 (0.03 MB
XLS)
Methods S1
Found at: doi:10.1371/journal.pone.0008068.s010 (11.21 MB
PDF)
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